These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 17658374

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dual inhibition of the renin system by aliskiren and valsartan.
    Oparil S, Yarows SA, Patel S, Zhang J, Satlin A.
    Lancet; 2007 Sep 29; 370(9593):1126-7. PubMed ID: 17905160
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
    Wood JM, Schnell CR, Cumin F, Menard J, Webb RL.
    J Hypertens; 2005 Feb 29; 23(2):417-26. PubMed ID: 15662231
    [Abstract] [Full Text] [Related]

  • 7. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
    Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, Tanimoto T, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T.
    Hypertension; 2008 Sep 29; 52(3):563-72. PubMed ID: 18645051
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M, Ménard J, Bissery A, Guyene TT, Bura-Rivière A.
    Clin J Am Soc Nephrol; 2007 Sep 29; 2(5):947-55. PubMed ID: 17702736
    [Abstract] [Full Text] [Related]

  • 11. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
    Chrysant SG.
    Drugs Today (Barc); 2010 Mar 29; 46(3):151-62. PubMed ID: 20467589
    [Abstract] [Full Text] [Related]

  • 12. Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.
    Yarows SA.
    Expert Rev Cardiovasc Ther; 2010 Jan 29; 8(1):19-33. PubMed ID: 20030022
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R, Frishman WH, Stier CT, Sica DA.
    Cardiol Rev; 2007 Jan 29; 15(5):242-56. PubMed ID: 17700383
    [Abstract] [Full Text] [Related]

  • 16. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
    Crespo MJ, Cangiano JL, Altieri PI, Escobales N.
    J Cardiovasc Pharmacol; 2012 Jun 29; 59(6):547-52. PubMed ID: 22370958
    [Abstract] [Full Text] [Related]

  • 17. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS, Ziogas J, Campbell DJ.
    Hypertension; 2014 Apr 29; 63(4):768-73. PubMed ID: 24420538
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
    Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Tokutomi Y, Matsuba S, Nako H, Nakagata N, Kaneko T, Ogawa H, Kim-Mitsuyama S.
    Hypertension; 2009 Sep 29; 54(3):633-8. PubMed ID: 19597038
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial.
    Udell JA, Morrow DA, Braunwald E, Swedberg K, Bode C, Rifai N, Brunel PC, Prescott MF, Ren F, Hoffman EB, Scirica BM.
    Clin Chem; 2013 Jun 29; 59(6):959-67. PubMed ID: 23509108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.